XTalks

MAY 17, 2023

The Foundation for the National Institutes of Health (FNIH) announced this week that the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC) has selected eight rare diseases for its clinical trial portfolio.

Gene Therapy 98

Gene Therapy Clinical Trials Clinical Trials Gene 98

Pharma Mirror

MARCH 31, 2022

Symbiosis Pharmaceutical Services Ltd (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and biopharmaceuticals including Advanced Therapeutical Medicinal Products (ATMPs), has announced the completion of a £1.3

Manufacturing 130

Manufacturing Contract Manufacturing Gene Therapy Research 130

Pharmaceutical Technology

JUNE 14, 2023

Biologics form 51% of the current global drugs pipeline (highest stage of development as pipeline) according to GlobalData’s Drugs database (as of February 7, 2023). It is critical that at the beginning of any relationship with a contract packager there’s transparency on all needs.

Contract Packaging 130

Contract Packaging Packaging Packaging Development 130

pharmaphorum

NOVEMBER 5, 2020

An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).

Gene Therapy 98

Gene Therapy Gene Drugs Contract Manufacturing 98

Pharmaceutical Technology

OCTOBER 27, 2022

The increasing regulation of biotech and manufacturing deals in the US could prompt foreign companies such as Chinese contract development and manufacturing organisations (CDMOs) to seek alternative targets in Europe or elsewhere. There are already nine Chinese-based companies with 14 US contract manufacturing facilities.

Manufacturing 267

Manufacturing Contract Manufacturing Gene Therapy Gene 267

pharmaphorum

NOVEMBER 12, 2020

UCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get control of its adeno-associated virus (AAV) capsid delivery platform and two research programmes in neurodegenerative diseases. The post UCB revs up its gene therapy drive with Handl acquisition appeared first on.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

Pharmaceutical Technology

JULY 29, 2022

In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs). The most common marketed drugs in this space aim to address the hyperammonaemia caused by the defective genes in this disorder. Future Possibilities.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

pharmaphorum

JANUARY 6, 2021

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases. The nomination of a first candidate in the collaboration that will advance into development triggers a $2.5

Gene Silencing 60

Gene Silencing Gene RNA Contract Manufacturing 60

Roots Analysis

JANUARY 14, 2024

With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

BioTech 365

APRIL 22, 2021

Forge Biologics to Present at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit Forge Biologics to Present at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit COLUMBUS, Ohio–(BUSINESS WIRE)–Forge Biologics, a hybrid gene therapy contract manufacturing and clinical stage therapeutic development company, … Continue (..)

Genetics 52

Genetics Manufacturing Medicine Contract Manufacturing 52

Roots Analysis

APRIL 15, 2024

These complex entities, such as antibodies, antibody drug conjugates, cell therapies, gene therapies, and therapeutic proteins, are highly specific molecules that are designed to precisely target biomarkers associated with a particular disease pathway.

Manufacturing 40

Manufacturing Production Contract Manufacturing Contamination 40

Drug Discovery World

MARCH 8, 2024

For International Women’s Day (IWD), Diana Spencer highlights DDW interviews with eight inspirational women leaders in drug discovery and development. Stefanie Dedeurwaerdere, UCB Stefanie Dedeurwaerdere is Global Strategy Lead for Pipeline Development in Global Epilepsy & Rare Syndromes at UCB. Read the interview.

Drugs 69

Drugs Gene Editing Contract Manufacturing Antibody 69

Drug Discovery World

MARCH 7, 2023

The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr Ballantyne served there as chief scientific officer. Dr John Ballantyne, co-founder of Aldevron, has invested $3 million in CureLab Oncology and CureLab Veterinary.

Contract Manufacturing 52

Contract Manufacturing DNA Clinical Trials Clinical Trials 52

The Pharma Data

MARCH 16, 2021

Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim’s deep experience in central nervous system (CNS) drug discovery and development alongside Lieber’s expertise in centrally acting COMT inhibitors. The Lieber Institute for Brain Development. Weinberger, M.D.,

Development 52

Development Contract Manufacturing Licensing Licensing 52

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Biopharmaceutical Excipient Manufacturing Market. Biopharmaceutical Excipient Manufacturing Market. Concluding Remarks.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Drug Discovery World

FEBRUARY 26, 2024

Perhaps the greatest example of this has come from CAR-T cell therapies, which have developed as treatments for aggressive lymphomas, particularly in childhood cancers. Stem cells act as the only other alternative to donor cells when developers want to take an allogeneic approach to their therapies. Why is this important?

Manufacturing 52

Manufacturing In-Vivo Development Production 52

Drug Discovery World

DECEMBER 14, 2023

With leading academic institutions and significant recent investment, Glasgow is shaping up to be an important centre for drug discovery and development in the UK. In another breakthrough, researchers at CVR identified the human gene BTN3A3, which is responsible for blocking most avian flu viruses from spilling over into people.

Drugs 75

Drugs Life Science Research Scientist 75

Roots Analysis

AUGUST 8, 2023

Disposable bioreactors have transformed the process of conventional biomanufacturing, and their adoption is increasing rapidly for production of various biologics, such as antibody, recombinant proteins, cell and gene therapy. There are a number of companies that are now involved in the development of advanced single use bioreactors.

Manufacturing 52

Manufacturing Production Marketing Gene Therapy 52

Roots Analysis

OCTOBER 3, 2023

Specifically in the healthcare industry, the development of novel bioreactor and fermenter technologies has led to significant advancement in bioprocessing, biomanufacturing, and synthetic biology, enabling the production of innovative bioproducts with high purity, yield, and quality.

Vaccination 40

Vaccination Vaccine Production Manufacturing 40

XTalks

APRIL 11, 2024

This could be seen as a positive for companies developing CAR T-cell therapies for autoimmune diseases and solid tumors. According to Carvykti co-developer Legend Biotech, across US treatment centers that offer both therapies, Carvykti holds around 80 percent of the late-line market share.

FDA Approval 52

FDA Approval Manufacturing Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 11, 2021

“Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. Wood, Ph.D., Leproust, Ph.D.,

Antibody 52

Antibody DNA Containment Manufacturing 52

XTalks

FEBRUARY 27, 2024

XTALKS WEBINAR: Development of CAR-T Cells for T-ALL Targeting CCR9 Live and On-Demand: Wednesday, March 6, 2024, at 11am EST (4pm GMT/UK) Register for this free webinar to explore the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL).

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52